Somatuline Predictive Factors in Acromegaly and NET (SOPRANo)

Ipsen

Status: Completed

Conditions: Neuroendocrine Tumours; Acromegaly

Treatments: Drug: Somatuline Autogel® 60, 90 or 120 mg

Study type: Observational

Funder types: Industry

Identifiers

NCT01840449

A-94-52030-240

Details and patient eligibility

About

The aim of the study is to identify predictive factors for the response to Lanreotide treatment in Acromegaly as well as in Neuroendocrine Tumours.

Enrollment: 156 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Written informed consent (also mandatory in case of retrospective documentation of subject data)
• Diagnosis of acromegaly or NET with the intention to be treated with ATG or already on treatment with ATG

Exclusion criteria

• The subject has already been included in this study
• Participation in an interventional trial

Trial design

156 participants in 2 patient groups

Neuroendocrine Tumours

Description:

The subject will receive treatment as prescribed by the investigator and in accordance with the current recommendations, routine practice and local regulations.

Treatment:

Drug: Somatuline Autogel® 60, 90 or 120 mg

Acromegaly

Description:

The subject will receive treatment as prescribed by the investigator and in accordance with the current recommendations, routine practice and local regulations.

Treatment:

Drug: Somatuline Autogel® 60, 90 or 120 mg